FDA Expands Approval for ImmunityBio's Bladder Cancer Drug ANKTIVA
ImmunityBio, Inc. (IBRX) secured expanded approval from the U.S. Food and Drug Administration for its therapy ANKTIVA when used alongside BCG. The regulatory update extends treatment to patients diagnosed with papillary-only non-muscle invasive bladder cancer that failed to respond to standard therapy, making it the first approved medicine for this patient group.
With this decision, ANKTIVA's clinical label now covers the entire population of patients with BCG-unresponsive non-muscle invasive bladder cancer, including carcinoma in situ cases. In clinical testing, 62% of 77 evaluated patients achieved a complete response. Among those who responded, 58% maintained the response for 12 months or longer, and 40% maintained it for at least 24 months. Side effects were mostly mild to moderate grade 1 and 2 events, such as painful or frequent urination and blood in the urine.
Following the update, shares of ImmunityBio Inc traded up 1.12% to $9.91. Market participants will watch how the broader patient population coverage influences real-world treatment adoption and commercial performance going forward.
Key points
- The FDA expanded ANKTIVA's label to include BCG-unresponsive non-muscle invasive bladder cancer patients with papillary-only tumors.
- This approval marks the first authorized treatment specifically for papillary-only BCG-unresponsive patients.
- Clinical trial data showed a 62% complete response rate, with 58% of responders maintaining results for at least 12 months.
- Most reported side effects were grade 1 or 2, including dysuria, urinary frequency, and hematuria.
- ImmunityBio Inc stock rose 1.12% to $9.91 following the regulatory expansion.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What is the new FDA approval for ImmunityBio's ANKTIVA?
The FDA expanded ANKTIVA's indication to include patients with papillary-only non-muscle invasive bladder cancer that is unresponsive to BCG, making it the first approved treatment for this group.
How effective was ANKTIVA in clinical trial results?
In clinical testing, 62% of 77 patients achieved a complete response, with 58% of responders maintaining it for at least 12 months and 40% for at least 24 months.
What side effects were reported with ANKTIVA treatment?
Most treatment-related adverse events were grade 1 to 2, consistent with BCG instillation, including painful urination, frequent urination, and blood in the urine.